^
Association details:
Biomarker:VEGFB expression
Cancer:Hepatocellular Cancer
Drug Class:CLDN1 inhibitor
Direction:Resistant
Evidence:
Evidence Level:
Resistant: D – Preclinical
Title:

A humanized Claudin-1 specific monoclonal antibody for treatment of hepatocellular carcinoma

Published date:
06/26/2021
Excerpt:
Furthermore, CLDN1 mAbs markedly and significantly suppressed epithelial-mesenchymal transition (EMT) and matrix metalloproteinase synthesis in tumor cells. Good treatment response in PDX models correlated with expression of genes that are associated with a fibrotic tumor environment, whereas presence of the angiogenic factor VEGFB predicted low treatment efficacy.